BeiGene, Ltd (BGNE)

Etorro trading 970x250
BeiGene, Ltd (BGNE) Logo

About BeiGene, Ltd

BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People’s Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin’s lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company’s clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company was incorporated in 2010 and is headquartered in Beijing, the People’s Republic of China. Address: No.30 Science Park Road, Beijing, China, 102206

BeiGene, Ltd News and around…

Latest news about BeiGene, Ltd (BGNE) common stock and company :

Week In Review: Hansoh Signs $456 Million Deal For siRNA Products
16 Oct, 2021 FinancialContent

Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. Hansoh will make an upfront payment of $6.5 million and up to $450 million in milestones.

Analysts are Cutting Price Targets of These 10 Stocks
15 Oct, 2021 Yahoo! Finance

In this article, we discuss the 10 stocks that analysts are cutting price targets of. If you want to skip our detailed analysis of these stocks, go directly to Analysts are Cutting Price Targets of These 5 Stocks. Two top economic experts have warned that there are signs that the United States economy is headed […]

2 Penny Stocks That Could Soar Soon
14 Oct, 2021 FinancialContent

These two tiny drugmakers might be hidden gems.

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021
12 Oct, 2021 FinancialContent

Upgrades For Callaway Golf Co (NYSE:ELY), Compass Point upgraded the previous rating of Neutral to Buy. Callaway Golf earned $0.36 in ...

BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia
10 Oct, 2021 FinancialContent

BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia

BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma
10 Oct, 2021 Yahoo! Finance

SYDNEY & CAMBRIDGE, Mass. & BEIJING, October 10, 2021--BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström’s Macroglobulinemia
07 Oct, 2021 FinancialContent

BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA® (zanubrutinib) has been approved in Australia for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or in first line treatment for patients unsuitable for chemo-immunotherapy.1 Following registration of BRUKINSA with the Australia Therapeutic Goods Administration (TGA), these patients will have immediate access to BRUKINSA through a BeiGene sponsored post-approval, pre-reimbursement access program.

3 Biotech Stocks That Surged in September
05 Oct, 2021 FinancialContent

Find out why last month was a big one for these three drugmakers.

This Potential Indication Could Be a Winner for Novartis
29 Sep, 2021 FinancialContent

The U.S. Food and Drug Administration accepted Novartis' filing for tislelizumab to treat esophageal cancer.

Notable Beigene Insider Trades $3.11 Million In Company Stock
23 Sep, 2021 FinancialContent

Jane Huang, Cmo And Hematology at Beigene (NASDAQ:BGNE), made a large buy and sell of company shares on September 20, according to a new ...

BeiGene Announces Inclusion in FTSE Russell Indices
20 Sep, 2021 FinancialContent

BeiGene announced inclusion in several FTSE Russell indices.

48 Biggest Movers From Friday
20 Sep, 2021 FinancialContent

Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded ...

Why BeiGene Shares Are Rising
17 Sep, 2021 FinancialContent

Beigene Ltd (NASDAQ: BGNE)shares are trading higher by 3.8% at $400 after the company announced it received a positive CHMP ...

Why BeiGene's Shares Jumped on Friday
17 Sep, 2021 FinancialContent

The Chinese pharmaceutical company is racking up approvals for its lead oncology drug, Brukinsa.

Beigene Insider Trades $33.79 Million In Company Stock
17 Sep, 2021 FinancialContent

John Oyler, Chief Executive Officer at Beigene (NASDAQ:BGNE), made a large insider sell on September 15, according to a new SEC filing. ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
17 Sep, 2021 FinancialContent

Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 53.98% to $3.48 during Friday's pre-market ...

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia
17 Sep, 2021 FinancialContent

BeiGene (NASDAQ: BGNE; HKEX: 06160) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or first-line treatment for patients unsuitable for chemo-immunotherapy.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
17 Sep, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips There's only one day of trading left so let's start it off right with a look at the biggest pre-market stock movers for Friday. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

15 Stocks Moving in Friday's Pre-Market Session
17 Sep, 2021 FinancialContent

Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) rose 42% to $3.21 in pre-market trading. AbCellera Biologics Inc. (NASDAQ: ...

Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial
16 Sep, 2021 FinancialContent

At the European Society of Medical Oncology Congress 2021 (ESMO21), Zymeworks Inc (NYSE: ZYME) presented encouraging early data on ...

Notable Beigene Insider Makes $4.62 Million Sale
16 Sep, 2021 FinancialContent

Jane Huang, Cmo And Hematology at Beigene (NASDAQ:BGNE), made a large insider sell on September 13, according to a new SEC ...

BeiGene (BGNE) Scores Third FDA Nod for Brukinsa in Lymphoma
16 Sep, 2021 Yahoo! Finance

The FDA grants accelerated nod to BeiGene's (BGNE) Brukinsa for treating adults with relapsed or refractory marginal zone lymphoma. This marks the third approval for the drug in the United States.

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
16 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Leap Therapeutics Stock Is Moving Higher On Updated DKN-01 Combo Trial Data In Gastric Cancer
16 Sep, 2021 FinancialContent

Leap Therapeutics Inc(NASDAQ: LPTX) announcedupdated data from the first-line cohortof the DisTinGuish Phase 2a ...

Analysis-China's biotech sector comes of age with big licensing deals, global ambitions
15 Sep, 2021 Yahoo! Finance

If investors in China's biotech industry needed one more sign that the sector is coming of age, then a major licensing deal RemeGen Co Ltd struck last month with Seattle-based Seagen Inc fits the bill. The agreement to co-develop cancer treatments using a RemeGen antibody drug conjugate is regarded as one of the biggest of its kind between a Chinese biotech and a Western firm. Nearly all were signed in the past year, underscoring China's still small but growing role in developing innovative cancer drugs that will be used worldwide.

3 Top Chinese Stocks to Watch in September
15 Sep, 2021 FinancialContent

There are plenty of risks, but the rewards could be great.

BeiGene's Brukinsa Scores FDA Approval For Marginal Zone Lymphoma
15 Sep, 2021 FinancialContent

TheFDA has granted accelerated approvaltoBeiGene Ltd's(NASDAQ: BGNE) Brukinsa (zanubrutinib) for relapsed ...

The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
15 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
15 Sep, 2021 FinancialContent

U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma

BeiGene, Ltd (BGNE) is a NASDAQ Common Stock listed in , ,

970x250